Russia at a glance
- Population
- 143.5 million 2025
- Life expectancy at birth
- 73.4 years, 2024
- People aged 65 and over
- 17.8 % of people, 2025
- Health spending per person
- 1,003 US$ per person, 2023
- Doctors
- 5.11 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Russia Sickle Cell Disease Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$122.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $30.0 Mn | — | — |
| 2025 (base) | $35.4 Mn | +$5.4 Mn | — |
| 2026 (forecast) | $41.8 Mn | +$6.4 Mn | +18.1% |
| 2027 (forecast) | $49.4 Mn | +$7.6 Mn | +39.5% |
| 2028 (forecast) | $58.4 Mn | +$8.9 Mn | +64.7% |
| 2029 (forecast) | $68.9 Mn | +$10.6 Mn | +94.5% |
| 2030 (forecast) | $81.4 Mn | +$12.5 Mn | +129.7% |
| 2031 (forecast) | $96.1 Mn | +$14.7 Mn | +171.3% |
| 2032 (forecast) | $113.5 Mn | +$17.4 Mn | +220.4% |
| 2033 (forecast) | $134.1 Mn | +$20.5 Mn | +278.4% |
| 2034 (forecast) | $158.3 Mn | +$24.3 Mn | +346.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $35.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $158.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Sickle Cell Disease Treatment |
| Segments | Treatment, age and end user (see all) |
| Key players | Vertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG, Novo Nordisk A/S (see all) |
| Regulator in Russia | Ministry of HealthSource: Ministry of Health of the Russian Federation. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Sickle cell disease therapeutics include gene therapies, gene editing and medicines that reduce pain crises and organ damage.
Key segments of the sickle Cell Disease Therapeutics market include treatment (Gene Therapy, Gene Editing and Hydroxyurea) and age (Pediatric and Adult).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the sickle Cell Disease Therapeutics market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the sickle Cell Disease Therapeutics market. Payers are still working out how to pay for one-time cures.
The sickle Cell Disease Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are registered by the Ministry of Health, under Eurasian Economic Union rules.[1] Compulsory medical insurance (OMS) pays for a guaranteed package of free care, through the Federal Compulsory Medical Insurance Fund.[2]
[1] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[2] Federal Compulsory Medical Insurance Fund. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sickle Cell Disease Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Russia.
What doctors and scientists are doing in Sickle Cell Disease Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
Russia · 1 shared keyword
Russia · 1 shared keyword
Russia · 1 shared keyword
Russia · 1 shared keyword
Russia · 1 shared keyword
Russia · 1 shared keyword
Digital Health · Russia
Healthcare Services · Russia
Healthcare Services · Russia
Medical Devices · Russia
Digital Health · Russia
Medical Devices · Russia